Castelo-Branco C, Casals E, Sanllehy C, Fortuny A, Vanrell J A, González-Merlo J
Department of Gynecology and Obstetrics, School of Medicine, University of Barcelona, Spain.
J Reprod Med. 1995 Apr;40(4):305-11.
Several studies have demonstrated that the use of estrogens in postmenopausal women has a protective effect against cardiovascular disease; however, this beneficial effect may be counteracted when concomitant progestogens are administered. We investigated the influence of hormone replacement therapy (HRT) with lower doses of medroxyprogesterone acetate (MPA) (2.5 mg/d) on the endometrium and on the plasma levels of lipids, lipoproteins and apolipoproteins. All the studied HRT regimens induced favorable changes in the levels of plasma lipids, lipoproteins and apolipoproteins, which may play an important role in the prevention of cardiovascular disease. The dosage of 2.5 mg/d of MPA is clearly inadequate to protect the endometrium from hyperplastic changes with sequential regimens, but probably this dosage is safe when MPA is administered continuously.
多项研究表明，绝经后女性使用雌激素对心血管疾病具有保护作用；然而，当同时使用孕激素时，这种有益作用可能会被抵消。我们研究了低剂量醋酸甲羟孕酮（MPA）（2.5毫克/天）的激素替代疗法（HRT）对子宫内膜以及血脂、脂蛋白和载脂蛋白血浆水平的影响。所有研究的HRT方案均引起血浆脂质、脂蛋白和载脂蛋白水平的有利变化，这可能在预防心血管疾病中起重要作用。对于序贯方案，2.5毫克/天的MPA剂量明显不足以保护子宫内膜免受增生性变化影响，但当持续给予MPA时，该剂量可能是安全的。
